Huawei Says It Will Support AI Drug Development Without Developing Drugs
Huawei Pharmaceutical Group president Fan Jie said the company will not develop drugs or drug pipelines, according to IT之家. Huawei plans to provide pharmaceutical companies, research institutions and AI drug developers with computing, storage, networking, toolchains and data-governance capabilities. Fan also said some partner projects have begun deploying hundred-GPU computing clusters for training, deploying and optimizing drug-development models.
The statement clarifies Huawei’s role in AI drug development as an infrastructure and ecosystem provider rather than a drug developer, while the reported cluster deployments show that partner projects have begun using this model.
#Huawei#Huawei Pharmaceutical Group#DeepWise#StoneWise#MoleculeMind#Shanghai Institute of Materia Medica#Changping Laboratory